Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, palifermin (Kepivance®) cannot be endorsed for use within NHS Wales for the treatment of mucositis |
||
|
||
Medicine details |
||
| Medicine name | palifermin (Kepivance®) | |
| Formulation | 6.25 mg powder for solution for injection | |
| Reference number | 234 | |
| Indication | For use within NHS Wales for the treatment of mucositis. |
|
| Company | Swedish Orphan Biovitrum Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | Not available | |
| Date of issue | 28/06/2007 | |